Futura Medical Partners with OCT Clinical to Run FM71 Study
Futura Medical has partnered with OCT Clinical to run its FM71 clinical study for MED3000 in erectile dysfunction in four countries: Bulgaria, Poland, Georgia, and the USA. The companies have already reported the first patient entering the screening in Georgia earlier this week.
MED3000, is a topical gel developed specifically for the treatment of erectile dysfunction ("ED"). It is a fast-acting topical treatment which has the potential to be a highly differentiated product by addressing significant unmet needs in the ED market including speed of onset, safety, and tolerability.
The OCT Clinical team has already obtained study approval in Georgia where site initiation has been started: 50% of sites have been opened and the first patients have been screened.
As soon as the clinical trial application approvals are obtained from the regulatory authorities in Bulgaria, Poland, and the USA the CRO will start site initiation in these countries. For this project, the OCT Clinical team will engage the total of 18 research sites.
This is a multi-center, randomized, open-label, home use, parallel group, clinical investigation of topically-applied MED3000 gel and oral tadalafil tablets for the treatment of erectile dysfunction (ED) over a 24-week period. This clinical investigation is intended to assess the efficacy and safety of MED3000 gel in 100 male patients clinically diagnosed with a mix of mild, moderate, and severe ED. The enrollment target will include 20 African American patients (from the US) and 80 patients from Eastern Europe, who will undergo a seven-month study.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
